Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis
has funding vehicle: Consejo Nacional de Ciencia y Tecnología, CONACYT: UASLP‐CA‐28
related by: authorship_44149
related by: authorship_44145
related by: authorship_44148
related by: authorship_44144
crisid: 6737
freetext keyword: acetyl-isoniazid; isoniazid; pyrazinamide; rifampicin; tuberculosis High performance liquid chromatography; Liquids; Patient monitoring; Patient treatment; Pharmacokinetics; Quality control; Antituberculosis; Coefficient of variation; Maximum concentrations; Pharmacokinetics parameters; Plasma concentration; Therapeutic drug monitoring; Therapeutic range; Tuberculosis patients; Hydrazine; acetylisoniazid; isoniazid; isoniazid plus pyrazinamide plus rifampicin; pyrazinamide; rifampicin; absorption half-life; adult; aged; analytic method; area under the curve; Article; blood analysis; drug bioavailability; drug clearance; drug distribution; drug monitoring; elimination half-life; elimination rate constant; female; high performance liquid chromatography; human; limit of detection; limit of quantitation; male; maximum concentration; pilot study; priority journal; quality control; quantitative analysis; reliability; time to maximum plasma concentration; tuberculosis
related by: authorship_44150
type: Document
chemicalscas: acetylisoniazid, 1078-38-2; isoniazid, 54-85-3, 62229-51-0, 65979-32-0; pyrazinamide, 98-96-4; rifampicin, 13292-46-1
abstract: The aim of this study was to establish and validate an alternative high-performance liquid chromatography method for simultaneous quantification of pyrazinamide, isoniazid, acetyl-isoniazid and rifampicin in plasma of patients under treatment for tuberculosis. The performed method was lineal (r2> 0.99) in the range of 2.00–50.00 μg/mL for pyrazinamide, 0.50–20.00 μg/mL for both acetyl-isoniazid and isoniazid, and 1.20–25.00 μg/mL for rifampicin. Precision and trueness were demonstrated with coefficient of variation < 15%25 and deviations < 15%25, respectively, for quality controls samples. The lower limits of quantification were 2.00, 0.50, 0.50, and 1.20 μg/mL for pyrazinamide, isoniazid, acetyl-isoniazid and rifampicin, respectively. The method was applied for the analysis of plasma from patients with tuberculosis. This method allowed ensuring reliable quantification of the target compounds and their pharmacokinetics parameters. In general, the mean values of maximum concentration of each antituberculosis drug were located within their respective reference therapeutic ranges. However, patients with sub-therapeutic plasma concentrations of isoniazid and rifampicin were detected. This is the first analytical technique that simultaneously quantifies isoniazid, acetyl-isoniazid, rifampicin, and pyrazinamide concentrations from plasma samples by high-performance liquid chromatography with ultraviolet/visible. The proposed method could be applied for therapeutic drug monitoring and pharmacokinetics studies of the four compounds throughout the treatment of tuberculosis patients. © 2020 Wiley-VCH GmbH
related by: authorship_44154
related by: authorship_44147
related by: authorship_44153
type: Information Content Entity
manufactures: Sanofi Aventis; Sigma Aldrich, United States
has funding vehicle: FAI C14FAI‐04‐040.40
has publication venue: Journal of Separation Science
type: Entity
type: Generically Dependent Continuant
doi: 10.1002/jssc.202000672
most specific type: Article
related by: authorship_44146
type: Article
issue: 2
origen: scopus
pmid: 33200497
volume: 44
estado: published
date time value: article date 6737
related by: authorship_44152
related by: authorship_44151
tradenames: rifater, Sanofi Aventis
most specific type: Document
type: Continuant
e iscopus: 2-s2.0-85097506078
page start: 521
page end: 529
type: Thing

Document
type: Class

Journal of Separation Science
type: Document
type: Continuant
type: Generically Dependent Continuant
type: Thing
type: Journal
type: Entity
type: Information Content Entity
type: Collection
type: Periodical
publication venue for: Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis

Continuant
type: Class

Entity
type: Class

FAI C14FAI‐04‐040.40
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Grant
type: Continuant
funding vehicle for: Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis

Consejo Nacional de Ciencia y Tecnología, CONACYT: UASLP‐CA‐28
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Grant
type: Continuant
funding vehicle for: Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis

Generically Dependent Continuant
type: Class

individual
rights: termsOfUse
date: 2026-08-25T07:00:21
publisher: vivo
type: Document
label: RDF description of Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis - http://orbis.uaslp.mx/vivo/individual/scopus6736

Article
type: Class

Information Content Entity
type: Class